QY Research Inc. (Global Market Report Research Publisher) announces the release of 2025 latest report “Fundus Disease Auxiliary Diagnosis Software- Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032”. Based on current situation and impact historical analysis (2020-2024) and forecast calculations (2026-2032), this report provides a comprehensive analysis of the global Fundus Disease Auxiliary Diagnosis Software market, including market size, share, demand, industry development status, and forecasts for the next few years.
The global market for Fundus Disease Auxiliary Diagnosis Software was estimated to be worth US$ 405 million in 2025 and is projected to reach US$ 614 million, growing at a CAGR of 6.2% from 2026 to 2032.
【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)】
https://www.qyresearch.com/reports/5775859/fundus-disease-auxiliary-diagnosis-software
1. Fundus Disease Auxiliary Diagnosis Software Market Summary
Fundus disease auxiliary diagnostic software is a type of medical software based on artificial intelligence technology. It aims to assist doctors in identifying and assessing fundus lesions by automatically analyzing fundus images. It can quickly detect characteristics of common fundus diseases such as diabetic retinopathy, age-related macular degeneration, and glaucoma, and provide lesion localization, severity grading, or risk warnings. Its core value lies in improving diagnostic efficiency and consistency, making it particularly suitable for large-scale screening scenarios and helping primary healthcare institutions compensate for insufficient specialized ophthalmological resources. However, the final diagnosis still requires confirmation by a doctor based on clinical judgment.
According to the latest research report from QYResearch, in terms of market size, the global Fundus Disease Auxiliary Diagnosis Software market size is projected to grow from USD 2.6 billion in 2025 to USD 12.8 billion by 2032, at a CAGR of 23% during the forecast period.
Development Trends:
1. From Single-Disease Screening to Multi-Disease Integration and End-to-End Treatment Management: Leading global products are evolving from single-function diabetic retinopathy screening to comprehensive diagnostic platforms integrating multiple fundus diseases. Simultaneously, their functional boundaries are extending from screening to the entire treatment process, encompassing lesion segmentation, quantitative analysis, treatment recommendations, and even prognosis prediction, deeply integrating into clinical workflows and becoming “intelligent assistants” for ophthalmologists.
2. “Hardware-Software Integration” Solutions and Cloud Platform Services Become the Mainstream Delivery Model: Simply providing software faces compatibility challenges. Therefore, the leading industry trend is deep collaboration or mergers and acquisitions with hardware manufacturers to launch integrated hardware-software intelligent devices. On the other hand, providing cloud-based SaaS services allows medical institutions to use the latest algorithms flexibly and at low cost through subscriptions, supporting multi-center data collaboration and remote diagnosis.
3. Clarified Regulatory Pathways and the Rise of Real-World Evidence (RWE): Regulatory agencies such as the US FDA and EU CE have established relatively clear approval pathways for AI medical devices. After approval, continuous product validation and upgrades become increasingly important, making post-market monitoring and algorithm iteration using real-world clinical data (RWE) crucial. This requires companies to build sustainable data loop capabilities to demonstrate their clinical effectiveness and safety.
Development Opportunities:
1. The increasing global burden on eye health and the uneven distribution of medical resources create rigid demand: The global population with visual impairment is large and this problem is exacerbated by aging. However, there is a severe shortage of professional ophthalmologists globally, especially in primary care and emerging markets. This provides a huge market space for AI-assisted diagnostic software, making it a core tool for large-scale early screening of fundus diseases and achieving “front-line intervention” in primary healthcare and physical examinations.
2. Chronic disease management and multi-disease-related screening bring incremental market growth: The fundus is the only window through which blood vessels and nerves can be observed non-invasively. Therefore, the software is not only used for eye diseases but is also being explored for assisting in the assessment of the risk and progression of systemic chronic diseases such as diabetes, hypertension, and Alzheimer’s disease. This “multiple diseases in one eye” screening model greatly expands its application value and payment scenarios in public health and health management.
3. Technological advancements and improved payment systems jointly open up commercialization opportunities: Multimodal AI can significantly improve diagnostic accuracy and disease insight depth, creating a technological leap. Meanwhile, some national health insurance and commercial insurance systems have begun to include validated AI-assisted diagnostic services in their reimbursement coverage. For example, Germany already has relevant health insurance codes, providing the industry with a clear payment path and accelerating commercialization.
Hindering Factors:
1. Global Compliance Challenges Regarding Data Privacy, Security, and Cross-Border Flow: Medical data is strictly protected by various countries, and acquiring high-quality, large-scale, labeled training data is extremely costly and complex. Requirements for data anonymization, localized storage, and restrictions on cross-border transfer create significant legal and operational obstacles to collecting data and deploying a unified product globally.
2. High Standards of Clinical Validation and the Complexity of Integrating with Physician Workflows: Obtaining approval from global regulatory agencies across different ethnicities and devices requires expensive and time-consuming multi-center clinical trials to demonstrate generalization ability and clinical efficacy. Furthermore, successful approval is only the first step; seamlessly and efficiently integrating the software into the diverse clinical workflows and hospital information systems of different countries and hospitals is crucial to the actual adoption rate of the product.
3. Immature Business Models and Payment Systems with Significant Regional Differences: While the prospects are promising, in most parts of the world, AI-assisted diagnosis, as a new service, still generally lacks a clear charging entity, pricing standards, and insurance reimbursement mechanisms. Companies need to engage in lengthy negotiations with healthcare payers and hospitals in various countries, exploring various models such as pay-per-use, device bundling, and subscription systems. Establishing a closed-loop business model is fraught with uncertainty.
Barriers:
1. Extremely High Regulatory and Certification Barriers: In major markets, this type of software is typically classified as a Class II or Class III medical device, requiring stringent regulatory approval. This process demands tens of millions of dollars and years of time, involving complex clinical study designs, results submission, and defense, creating a formidable entry barrier for newcomers.
2. Technical Barriers of High-Quality Data Loop and Algorithm Iteration: Building a globally competitive product requires not only a top-tier AI algorithm team but also the ability to continuously acquire high-quality clinical data from multiple regions, populations, and devices, and establish a closed-loop system involving physician participation in annotation, algorithm training, validation, and updates. Such data acquisition capabilities and clinical collaboration networks require long-term accumulation and are difficult to replicate quickly.
3. Ecosystem Barriers of Clinical Trust and Market Channels: Gaining the trust of ophthalmologists is crucial for product adoption. This requires companies to possess deep medical knowledge, collaborate with top clinical experts in research and development, and build academic reputation through high-level academic papers and real-world use cases. Furthermore, establishing a global direct sales network or partnerships with local distributors and medical device giants also requires significant investment and time.
The report provides a detailed analysis of the market size, growth potential, and key trends for each segment. Through detailed analysis, industry players can identify profit opportunities, develop strategies for specific customer segments, and allocate resources effectively.
The Fundus Disease Auxiliary Diagnosis Software market is segmented as below:
By Company
Thirona Retina B.V.(Icare Finland Oy)
Acer Medical
Delft Imaging Systems
Beijing Zhiyuan Huitu Technology Co., Ltd.
Beijing Yingtong Technology Development Co., Ltd.
Shenzhen Siji Intelligent Technology Co., Ltd.
WeDoctor (Fujian) Medical Devices Co., Ltd.
Voxelcloud
Beijing Zhizhen Internet Technology Co., Ltd.
Kangfuzi Health
Tencent Medical Health
Segment by Type
Client Software
Server Software
Segment by Application
Hospital
Clinic
Others
Each chapter of the report provides detailed information for readers to further understand the Fundus Disease Auxiliary Diagnosis Software market:
Chapter 1: Introduces the report scope of the Fundus Disease Auxiliary Diagnosis Software report, global total market size (valve, volume and price). This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry. (2021-2032)
Chapter 2: Detailed analysis of Fundus Disease Auxiliary Diagnosis Software manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc. (2021-2026)
Chapter 3: Provides the analysis of various Fundus Disease Auxiliary Diagnosis Software market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments. (2021-2032)
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.(2021-2032)
Chapter 5: Sales, revenue of Fundus Disease Auxiliary Diagnosis Software in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world..(2021-2032)
Chapter 6: Sales, revenue of Fundus Disease Auxiliary Diagnosis Software in country level. It provides sigmate data by Type, and by Application for each country/region.(2021-2032)
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc. (2021-2026)
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.
Benefits of purchasing QYResearch report:
Competitive Analysis: QYResearch provides in-depth Fundus Disease Auxiliary Diagnosis Software competitive analysis, including information on key company profiles, new entrants, acquisitions, mergers, large market shear, opportunities, and challenges. These analyses provide clients with a comprehensive understanding of market conditions and competitive dynamics, enabling them to develop effective market strategies and maintain their competitive edge.
Industry Analysis: QYResearch provides Fundus Disease Auxiliary Diagnosis Software comprehensive industry data and trend analysis, including raw material analysis, market application analysis, product type analysis, market demand analysis, market supply analysis, downstream market analysis, and supply chain analysis.
and trend analysis. These analyses help clients understand the direction of industry development and make informed business decisions.
Market Size: QYResearch provides Fundus Disease Auxiliary Diagnosis Software market size analysis, including capacity, production, sales, production value, price, cost, and profit analysis. This data helps clients understand market size and development potential, and is an important reference for business development.
Other relevant reports of QYResearch:
Global Fundus Disease Auxiliary Diagnosis Software Market Outlook, In‑Depth Analysis & Forecast to 2032
Global Fundus Disease Auxiliary Diagnosis Software Sales Market Report, Competitive Analysis and Regional Opportunities 2026-2032
Global Fundus Disease Auxiliary Diagnosis Software Market Research Report 2026
About Us：
QYResearch founded in California, USA in 2007, which is a leading global market research and consulting company. Our primary business include market research reports, custom reports, commissioned research, IPO consultancy, business plans, etc. With over 19 years of experience and a dedicated research team, we are well placed to provide useful information and data for your business, and we have established offices in 7 countries (include United States, Germany, Switzerland, Japan, Korea, China and India) and business partners in over 30 countries. We have provided industrial information services to more than 60,000 companies in over the world.
Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
Email: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp
